Sanofi finds success in clinical trial for smoker’s lungs

Sanofi has emphasized the rapid and sustained benefits of its collaborative anti-inflammatory medication, Dupixent, developed in partnership with Regeneron, in a clinical trial targeting smoker’s lung. These advantages became evident early on in the trial and persisted throughout the one-year study period.

The business stated that it is speaking with key regulatory bodies across the world whether the trial results are strong enough to guarantee a regulatory review or whether the results of another current study will be required.

Sanofi is a healthcare pharmaceutical business which was originated in France and has operations in different parts of the world. The company was founded in 1973 having a legacy of almost 50 years.  Sanofi is primarily involved in the R&D, production, and marketing of pharmaceutical goods, although the company also creates over-the-counter treatments and has expertise in various medical fields, including cardiovascular, central nervous system, diabetes, cancer, thrombosis, and vaccines.

Regeneron Pharmaceuticals is a US-based biotechnology company with headquarters in New York. The firm was established in 1988 specializing in neurotrophic factors and their regeneration powers, and later expanded into the research of cytokine and tyrosine kinase receptors.

Dupixent, utilized for the treatment of allergic conditions like eczema, asthma, and chronic sinusitis caused by nasal polyps, is a monoclonal antibody that effectively inhibits interleukin 4 and interleukin 13. It can also be used to treat eosinophilic esophagitis and prurigo nodularis.

Sanofi revealed data on the successful trial at the American Thoracic Society meeting held in the US Capital city. The company saw signs of improvement in the functionality of the lungs within fourteen days of therapy, and this was also sustained out to 52 weeks.

Sanofi began a comparable second Chronic obstructive pulmonary disease (COPD) study to support the statistical reliability of the results, but it is unclear if regulators would begin a review immediately or wait for the results of the staggered second trial, which is scheduled at the start of 2024.

The company will discuss the results of the trial with the regulatory body and devise a solution before the commencement of the second trial.

Sanofi had previously predicted that Dupixent will have sales of up to 13 billion euros ($14.2 billion) in its best year as it aims to expand its usage across numerous inflammatory disorders, but it had omitted COPD from its sales target.

In a trial published in March, it was found that Dupixent, a drug developed by Sanofi, led to a significant decrease of 30% in acute exacerbations of chronic obstructive pulmonary disease (COPD).

The post Sanofi finds success in clinical trial for smoker’s lungs appeared first on LifeSci Voice.